Storia in 2 fonti

Leqembi records best quarter since launch as Biogen raises guidance

Leqembi posts record $184M in Q2, its third straight quarter of growth, as Biogen lifts full-year guidance and folds in Apellis.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo17 h fa

Leqembi records best quarter since launch as Biogen raises guidance

Leqembi posts record $184M in Q2, its third straight quarter of growth, as Biogen lifts full-year guidance and folds in Apellis.

originale

benzinga.com9 h fa

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio - Biogen (NASDAQ:BII

Biogen raised FY2026 guidance to $15.85–$16.85 (consensus $12.83) on Leqembi growth and $128M from Apellis acquisition. Dual strategy—M&A consolidation plus pipeline validation in MS/ALS—reflects big pharma de-risking for sustainable margins.

Leggi questa versione → originale

Timeline cronologica

mercoledì 29 luglio 2026·endpoints.news
Leqembi records best quarter since launch as Biogen raises guidance
Leqembi posts record $184M in Q2, its third straight quarter of growth, as Biogen lifts full-year guidance and folds in Apellis.
mercoledì 29 luglio 2026·benzinga.com
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio - Biogen (NASDAQ:BII
Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.